Last Updated: 01/03/2024

Novel oral combination formulation for the treatment of resistant malaria (Plasmodium falciparum) comprising a/ß arteether and Lumifantrine

Objectives

This project explores a novel oral combination formulation for the treatment of resistant malaria (Plasmodium falciparum) comprising a/ß arteether and Lumifantrine.

Principal Institution

Central Drug Research Institute (CSIR-CDRI), India

Principal Investigators / Focal Persons

Prabhat R. Mishra

Themes

Drug Resistance
Drug-based Strategies

Date

Mar 2019 — Mar 2022

Total Project Funding

$36,816

Funding Details
Department of Biotechnology (DBT), India

Grant ID: BT/HRD/35/01/03/2019
Project Site

India

SHARE

Related Resources

Antimalarial drug resistance in uncomplicated and severe falciparum malaria in Asia and Africa
Multimedia

Related Projects

Dec 2025 —
Dec 2026
A Phase IIb Randomised Controlled Trial of the Safety, Immunogenicity and Efficacy of the Malaria Vaccine Candidates R78C With Matrix-M™, and the Combination of RH5.1 and R21 With Matrix-M™, in Children Aged 5-36 Months in Burkina Faso
Research Institute of Health Sciences (IRSS), Burkina Faso
Mar 2022 —
Feb 2025

$460,773

A multi-centre randomised controlled non-inferiority trial to compare the efficacy, safety and tolerability of Triple Artemisinin-based Combination Therapies versus first-line ACTs + placebo for the treatment of uncomplicated Plasmodium falciparum malaria in Africa (DeTACT-AFRICA Study)
Jun 2024 —
Jun 2029

$680,485

Optimising strategic combinations of malaria interventions in western Kenya through a mechanistic model
Liverpool School of Tropical Medicine (LSTM), United Kingdom
SHARE